glp·helper
glphelper.com/ozempic/louisiana/baton-rouge
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® providers &
prescriptions in Baton Rouge, LA

Verified Ozempic providers in Baton Rouge, LA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Ozempic weight loss →trial-anchored estimate
city providers
35
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Louisiana
35 of 35 shown

Find an Ozempic provider in Louisiana.

Every entry is checked against the NPI registry and the Louisiana medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Louisiana city · /ozempic/louisiana/{city}
§ 03Getting Ozempic in Baton Rouge
35 providers · Baton Rouge, LA

How to get Ozempic in Baton Rouge.

35 GLP-1 prescribers and 7 local resource types are on record for Baton Rouge, plus 2 nearby towns in the directory.

Prescribers in Baton Rouge
35 prescribers
35 GLP-1 prescribers in Baton Rouge, most listed as Family Medicine (14), Internal Medicine, Endocrinology, Diabetes & Metabolism (13) and Internal Medicine (6). Any Louisiana-licensed physician, nurse practitioner, or PA can prescribe Ozempic, over video or in person. The nearest towns on record are New Orleans (39 providers) and Shreveport (34 providers).
Around the prescription in Baton Rouge
7 listed nearby
6 dietitians, 6 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Baton Rouge.
Medicaid (weight loss)
Diabetes only
As of April 2026, Louisiana Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Louisiana’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes, and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In randomized trials it lowered HbA1c by 1.4 to 1.8 percentage points and produced a mean weight loss of 4.5 to 6.4 kg at the 1 mg dose.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

For the receptor story in plain English, read how does ozempic work.

Rapid weight loss can change the midface. The mechanism people call ozempic face is in the research notes.

At a glanceNDC 0169-4132
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Wegovy is the FDA-approved formulation for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Louisiana

Diagnosed diabetes reaches 14.6% of adults in Louisiana.

of Louisiana adults have obesity
39.2%
diagnosed diabetes
14.6%

Age-adjusted estimates for Louisiana, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight lossthe tirzepatide dosing schedule
§ 05Support around Ozempic in Baton Rouge
6 fitness clubs

The prescription is one part. Here is the rest, in Baton Rouge.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Baton Rouge, LA, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

UREC
REC CENTER
4.7 on Google · 246 reviews
LSU 102, Student Recreation Complex
Website
CLUB4 Fitness Baton Rouge FL
FITNESS
4.0 on Google · 177 reviews
9620 Florida Blvd #700
Website
The Beach Fitness Club
FITNESS
4.3 on Google · 156 reviews
4343 Rhoda Dr
Website
CORE UFC GYM Sherwood
FITNESS
4.9 on Google · 141 reviews
4520 S Sherwood Forest Blvd #110
Website
Refuge Aerial Fitness & Performance
FITNESS
5.0 on Google · 100 reviews
6031 Fieldstone Dr
Website
Neighborhood Barre Block BR
FITNESS
5.0 on Google · 79 reviews
inside THE BLOCK, 711 Jefferson Hwy Ste 1B
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Sheila Alford, RDN, LDN
RD
Registered dietitian
6400 Perkins Rd Bldg D1
Call 225-330-0497NPI 1093295560
Aquierra Anderson, RDN, LDN
RD
Registered dietitian
10202 Perkins Rowe Apt 2001
Call 662-458-5237NPI 1851936264
Cheryl Atkinson, PhD., RD., LDN
RD
Registered dietitian
7801 Scenic Highway
Call 225-354-4404NPI 1740376367
Kelly Atteberry, RD
RD
Registered dietitian
4625 Parkoaks Dr Apt 44
Call 225-229-9325NPI 1710815329
Jen Avis, R.D
RD
Registered dietitian
200 Professional Dr
Call 318-966-6535NPI 1801881115
Taylor Ayers
RD
Registered dietitian
634 Saint Joseph St
Call 225-489-1472NPI 1114751617
§ 06Clinical evidence
N = 8,416 across SUSTAIN 1 to 7

What the trials actually showed.

We summarize results from the SUSTAIN program, the seven Phase III randomized trials Novo Nordisk submitted to the FDA, and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1 through 7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.8%
vs. placebo at 30 wk[3]
Weight change
−4.5 to −6.4 kg
mean, 1 mg dose[3]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Ozempic weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in SUSTAIN trials were nausea (15 to 20%), diarrhea (8 to 9%), and vomiting (5 to 9%), all dose-dependent and typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15 to 20%
mild
Most common; typically dose-dependent and resolves within weeks
Diarrhea
8 to 9%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
3 to 7%
mild
Abdominal pain
5 to 7%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$950 to $1,150
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $250
per month copay
Varies by PBM; T2D indication usually covered
Commercial insurance (off-label / weight)
Typically denied
PA required; majority denied for weight indication
Medicare Part D
$0 to $100
per month
T2D covered; weight loss not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Ozempic providers in Louisiana

NPI-verified Ozempic (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Ozempic in other states

Find NPI-verified Ozempic (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Ozempic in Louisiana

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is a federally scheduled prescription drug in all 50 states. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription. No state permits pharmacist-initiated prescribing of GLP-1s.[1]